

Financial news for PCYC dated on 2016-08-22: Goldman Sachs Talks Pfizer's Acquisition Deal Of Medivation

Financial news for PCYC dated on 2015-06-15: JMP Sees A 'Negative Market Tone' In Biotechnology

Financial news for PCYC dated on 2015-05-28: Ibrutinib in Combination with Anti-PD-L1 Antibody (MEDI4736) Study Begins for Patients with Two Relapsed/Refractory Blood Cancers

Financial news for PCYC dated on 2015-05-28: Morgan Stanley Calls AbbVie 'Unpredictable' With 'Upside'

Financial news for PCYC dated on 2015-05-22: European Medicines Agency Releases Positive Opinion, Recommends Approval of IMBRUVICA To Treat Waldenstrom's Macroglobulinemia

Financial news for PCYC dated on 2015-05-22: CHMP Gave Six Recommendations on Extensions of Therapeutic Indication for: Janssen's Simponi and Stelara, Pharmacyclics' Imbruvica, Eisai's Fycompa, BioMarin's Kuvan, Novo's Xultophy

Financial news for PCYC dated on 2015-05-21: Benzinga's M&A Chatter for Thursday May 21, 2015

Financial news for PCYC dated on 2015-05-21: Abbvie Reports Offer Consideration for Purchase of Pharmacyclics: \$152.25/Share in Cash, 1.6639 Shares

Financial news for PCYC dated on 2015-05-05: Books for AbbVie's Jumbo Acquisition Bond for Pharmacyclics Acquisition Reach \$60B, According to Sources -Reuters

Financial news for PCYC dated on 2015-05-01: Pharmacyclics Reports Q1 EPS \$0.43 vs. Est. \$0.11, Rev. \$205.8M vs. Est. \$226.3M; EPS Estimate May Not Compare

Financial news for PCYC dated on 2015-04-23: From Conf Call: Abbvie Expects Accretion from Pharmacyclics Acquisition in Excess of \$0.60/Share in 2019, Rising to \$1.00+/Share By 2021

Financial news for PCYC dated on 2015-04-20: Pharmacyclics Shares Fall As Kyle Bass Files Petition To Cancel Patent

Financial news for PCYC dated on 2015-04-20: UPDATE: USPTO Filing Labeled April 20th On Pharmacyclics, Shows Hayman Lawyer Suggests Claims 1 & 2 Are 'Obvious,' 'Anticipated By NCT00849645'

Financial news for PCYC dated on 2015-04-20: Pharmacyclics Shares Fall As Kyle Bass Files Petition To Cancel Patent For IBRUTINIB, Suggests Patent Is 'Obvious'

Financial news for PCYC dated on 2015-04-20: Kyle Bass Files New IPR Patent Rexam Against Pharmacyclics Patent 8,754,090

Financial news for PCYC dated on 2015-04-20: CAR-T Therapy Stocks Hit Hard Following AACR Data

Financial news for PCYC dated on 2015-04-20: Pharmacyclics Reports IMBRUVICA Longer-Term Follow-Up Data Shows Durable Responses in Patients with CLL

Financial news for PCYC dated on 2015-04-17: It's A Big Weekend For Biotech

Financial news for PCYC dated on 2015-04-14: Why Johnson & Johnson's Strong Pharmaceutical Business Is A Concern

Financial news for PCYC dated on 2015-04-13: 7 Trends Drug Investors Should Know

Financial news for PCYC dated on 2015-04-09: New Longer-Term IMBRUVICA(r) (ibrutinib) Data Show High Rates Of Response in Patients with Waldenstrom's Macroglobulinemia

Financial news for PCYC dated on 2015-04-06: 16 Biotech Catalysts SunTrust Is Tracking

Financial news for PCYC dated on 2015-04-01: Solid Tumor Study Investigating Ibrutinib in Combination with Anti-PD-L1 Antibody Commences in Patients

Financial news for PCYC dated on 2015-03-26: New ETF From BlackRock And Edelman

Financial news for PCYC dated on 2015-03-16: Pharmacyclics Resumes Trading; Reason Not Available

Financial news for PCYC dated on 2015-03-16: Pharmacyclics Resumes Quoting, Trading Opens At 15:30PM EDT

Financial news for PCYC dated on 2015-03-16: PREVIEW: Pharmacyclics Shares to Resume Trading at 3:30 PM ET

Financial news for PCYC dated on 2015-03-16: UPDATE: Independent Data Monitoring Committee Unanimously Recommends Unblinding of IMBRUVICA

Financial news for PCYC dated on 2015-03-16: AbbVie Spikes Higher on Volume

Financial news for PCYC dated on 2015-03-16: Independent Data Monitoring Committee Unanimously Recommends Unblinding of IMBRUVICA(r) (ibrutinib) Phase III Combination HELIOS

Financial news for PCYC dated on 2015-03-16: Pharmacyclics Trading Halted; News Pending

Financial news for PCYC dated on 2015-03-06: Benzinga's Top Downgrades

Financial news for PCYC dated on 2015-03-06: Credit Suisse Reiterates Neutral, Raises PT On Pharmacyclics As Deal Looks Likely To Happen

Financial news for PCYC dated on 2015-03-06: Nomura Downgrades Pharmacyclics To Neutral

Financial news for PCYC dated on 2015-03-06: Leerink Swann Downgrades Pharmacyclics to Market Perform

Financial news for PCYC dated on 2015-03-06: Nomura Downgrades Pharmacyclics to Neutral, Raises PT to \$261.25

Financial news for PCYC dated on 2015-03-05: Benzinga's M&A Chatter for Thursday March 5, 2015

Financial news for PCYC dated on 2015-03-05: Analysts Mixed On Premium For Pharmacyclics

Financial news for PCYC dated on 2015-03-05: Biotech M&A Outlook Boosted By AbbVie Deal, Says This RBC Analyst

Financial news for PCYC dated on 2015-03-05: AbbVie CEO Says Too Early to Predict Whether Humira Patients Will Eventually be Switched to New Experimental Formulation; Says that Would Make Sense -Reuters

Financial news for PCYC dated on 2015-03-05: Wells Fargo Downgrades Pharmacyclics to Market Perform

Financial news for PCYC dated on 2015-03-05: Here's Why AbbVie's Pharmacyclics Deal Will Boost Revenue 5%

Financial news for PCYC dated on 2015-03-05: Benzinga's Volume Movers

Financial news for PCYC dated on 2015-03-05: Stocks Hitting 52-Week Highs

Financial news for PCYC dated on 2015-03-05: Morning Market Losers

Financial news for PCYC dated on 2015-03-05: UPDATE: Abbvie CEO Says Not Likely to Pursue Another Deal as Large as Pharmacyclics Near-Medium Term

Financial news for PCYC dated on 2015-03-05: Morning Market Gainers

Financial news for PCYC dated on 2015-03-05: UPDATE: AbbVie CEO Expects Imbruvica US Sales of \$1B in 2015; Peak Sales of \$7B+

Financial news for PCYC dated on 2015-03-05: From Conf Call: Abbvie CEO Says Pharmacyclics Acquisition Will Boost Earnings by \$0.60+/Share by 2019, Ramp Earnings Thereafter

Financial news for PCYC dated on 2015-03-05: Benzinga's Top #PreMarket Losers

Financial news for PCYC dated on 2015-03-05: Benzinga's Top #PreMarket Gainers

Financial news for PCYC dated on 2015-03-05: BTIG Research Downgrades Pharmacyclics to Neutral

Financial news for PCYC dated on 2015-03-05: US Stock Futures Up Ahead Of Jobless Claims, Factory Orders Data

Financial news for PCYC dated on 2015-03-05: AbbVie to Acquire Pharmacyclics for \$261.25/Share in Cash, Stock

Financial news for PCYC dated on 2015-03-04: Benzinga's M&A Chatter for Wednesday March 4, 2015

Financial news for PCYC dated on 2015-03-04: Report: Pharmacyclics Inc. To Be Acquired By Johnson & Johnson

Financial news for PCYC dated on 2015-03-04: UPDATE: J&J's Purchase of Pharmacyclics May Be Announced as Soon as Thursday

Financial news for PCYC dated on 2015-03-04: Hearing J&J Has Agreed to Purchase Pharmacyclics

Financial news for PCYC dated on 2015-03-04: Hearing FT Reporting J&J Near Deal to Purchase Pharmacyclics

Financial news for PCYC dated on 2015-03-03: Leerink: Pharmacyclics Is Now Worth \$240

Financial news for PCYC dated on 2015-03-03: Benzinga's Top Downgrades

Financial news for PCYC dated on 2015-03-03: Wedbush Downgrades Pharmacyclics To Neutral

Financial news for PCYC dated on 2015-03-03: Wedbush Downgrades Pharmacyclics to Neutral, Raises PT to \$234.00

Financial news for PCYC dated on 2015-02-27: Weekly Analyst Highlights: Oil, Tesla On Readers' Minds

Financial news for PCYC dated on 2015-02-27: Pharmacyclics Provides Update on BTK Inhibitor for Autoimmune Diseases

Financial news for PCYC dated on 2015-02-27: In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody

Financial news for PCYC dated on 2015-02-27: Benzinga's Top Downgrades

Financial news for PCYC dated on 2015-02-27: Credit Suisse Downgrades Pharmacyclics To Neutral

Financial news for PCYC dated on 2015-02-27: Credit Suisse Downgrades Pharmacyclics to Neutral, Raises PT to \$233.00

Financial news for PCYC dated on 2015-02-27: Goldman Sachs Downgrades Pharmacyclics to Neutral, Maintains \$184.00 PT

Financial news for PCYC dated on 2015-02-26: Credit Suisse Downgrades Pharmacyclics Amid Takeover Rumors

Financial news for PCYC dated on 2015-02-26: Credit Suisse Downgrades Pharmacyclics to Neutral, Raises PT to \$223.00

Financial news for PCYC dated on 2015-02-26: WallachBeth Downgrades Pharmacyclics to Hold

Financial news for PCYC dated on 2015-02-25: Benzinga's M&A Chatter for Wednesday February 25, 2015

Financial news for PCYC dated on 2015-02-25: Deutsche Bank On Pharmacyclics: 'We Do Not See Much Upside'

Financial news for PCYC dated on 2015-02-25: Pharmacyclics Rumor: How Some Wall Street Analysts Are Reacting

Financial news for PCYC dated on 2015-02-25: Deutsche Bank Downgrades Pharmacyclics to Hold

Financial news for PCYC dated on 2015-02-25: Adam Feuerstein @adamfeuerstein Tweet: Bernstein trading desk reaction to \$PCYC takeout rumor. Skeptical. pic.twitter.com/SxiF83x0mh

Financial news for PCYC dated on 2015-02-25: PCYC Shares Resume Now Up 13%

Financial news for PCYC dated on 2015-02-25: UPDATE: Pharmacyclics Said To Weigh Sale Of \$15B Drugmaker; Said To Attract Interest From J&J, Novartis

Financial news for PCYC dated on 2015-02-25: Pharmacyclics Said to Weigh Sale

Financial news for PCYC dated on 2015-02-25: PCYC Shares Halted

Financial news for PCYC dated on 2015-02-23: Biotech Stocks Moving Higher

Financial news for PCYC dated on 2015-02-19: Nomura Recap Of Stocks To Look Out For

Financial news for PCYC dated on 2015-02-19: Analysts Respond To Pharmacyclics' Q4 Results

Financial news for PCYC dated on 2015-02-19: Nomura Upgrades Pharmacyclics, Sees 'Upside' To Stock

Financial news for PCYC dated on 2015-02-19: Benzinga's Top Downgrades

Financial news for PCYC dated on 2015-02-19: JP Morgan Downgrades Pharmacyclics To Neutral

Financial news for PCYC dated on 2015-02-19: JP Morgan Downgrades Pharmacyclics to Neutral, Raises PT to \$173.00

Financial news for PCYC dated on 2015-02-19: Nomura Upgrades Pharmacyclics to Buy, Raises PT to \$196.00

Financial news for PCYC dated on 2015-02-19: Roth Capital Downgrades Pharmacyclics to Neutral

Financial news for PCYC dated on 2015-02-18: Pharmacyclics Reports Q4 Adj. EPS \$0.96 vs \$0.76 Est., Sales \$290.2M; Reaffirms FY15 Outlook

Financial news for PCYC dated on 2015-02-17: Pharmacyclics Reports IMBRUVICA Treatment Shows Efficacy, Tolerability in Heavily-Treated Chronic Lymphocytic Leukemia Patients Following Allogeneic Stem Cell Transplant

Financial news for PCYC dated on 2015-02-11: JMP Securities Covers Mostly Good News From Pharma Pending More Visibility

Financial news for PCYC dated on 2015-02-06: Pharmacyclics Receives Orphan Drug Designation from FDA Related to Ibrutinib for Treatment of Nodal Marginal Zone Lymphoma

Financial news for PCYC dated on 2015-01-30: Stocks That Battle Cancer Were The Best-Performing Biotechs In January

Financial news for PCYC dated on 2015-01-29: FDA Announces Expansion of Approved Use of Pharmacyclic's Imbruvica for Rare Form of NHL

Financial news for PCYC dated on 2015-01-15: 10 Biotech Stories You Might've Missed This Week

Financial news for PCYC dated on 2015-01-13: Mid-Day Market Update: Pharmacyclics Surges On Strong Preliminary 2014 Results; Fresh Market Shares Slip

Financial news for PCYC dated on 2015-01-13: Mid-Morning Market Update: Markets Open Higher; Alcoa Profit Beats Expectations

Financial news for PCYC dated on 2015-01-13: Benzinga's Volume Movers

Financial news for PCYC dated on 2015-01-13: Morning Market Gainers

Financial news for PCYC dated on 2015-01-13: Tuesday Morning Movers: ChannelAdvisor Plummets

Financial news for PCYC dated on 2015-01-13: Pharmacyclics Shares Rise 14% Premarket on Strong Preliminary 2014 Results

Financial news for PCYC dated on 2015-01-12: Pharmacyclics Shares Rise 13% After-Hours on Strong Preliminary Results

Financial news for PCYC dated on 2015-01-12: Pharmacyclics Announces Favorable Preliminary 2014 U.S. Net Product Revenue Results

Financial news for PCYC dated on 2015-01-12: PCYC Shares Halted News Pending

Financial news for PCYC dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

Financial news for PCYC dated on 2015-01-06: UPDATE: BTIG Initiates Coverage On Pharmacyclics

Financial news for PCYC dated on 2015-01-05: BTIG Research Initiates Coverage on

Pharmacyclics at Buy, Announces \$225.00 PT

Financial news for PCYC dated on 2015-01-05: IMBRUVICA Data Demonstrates Efficacy in Previously Untreated and Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients

Financial news for PCYC dated on 2015-01-05: Nomura Downgrades Pharmacyclics to Neutral, Lowers PT to \$158.00

Financial news for PCYC dated on 2014-12-22: Pharmacyclics Offers Update on IMBRUVICA WM Submission

Financial news for PCYC dated on 2014-12-09: Pharmacyclics Reports IMRUVICA Data Shows Safety, Durability of Response at Two-Year Follow-Up in Mantle Cell Lymphoma

Financial news for PCYC dated on 2014-12-08: Pharmacyclics Reports IMBRUVICA Data Demonstrates Safety and Durability of Response at 2-Year Follow-up in Mantle Cell Lymphoma

Financial news for PCYC dated on 2014-12-06: Pharmacyclics Announces Promising IMBRUVICA Data in Multiple Myeloma

Financial news for PCYC dated on 2014-12-05: Pharmacyclics Announces Launch Of informCLL Registry

Financial news for PCYC dated on 2014-12-01: Pharmacyclics Annunces New IMBRUVICA Application Accepted by EMA for Waldenstrom's Macroglobulinemia

Financial news for PCYC dated on 2014-11-05: Nomura Maintains Buy on Pharmacyclics, Inc., Raises PT to \$175.00

Financial news for PCYC dated on 2014-11-05: Morgan Stanley Maintains Equal-weight on Pharmacyclics, Inc., Raises PT to \$111.00

Financial news for PCYC dated on 2014-11-04: Pharmacyclics, Inc. Reports Q3 EPS of \$0.69 Which May Not Compare \$0.37 Est; Revenue of \$207.10M Which May Not Compare \$201.51M Est

Financial news for PCYC dated on 2014-11-04: AstraZeneca And Pharmacyclics Enter Clinical Trial Collaboration To Evaluate Imbruvica In Hematologic Cancers

Financial news for PCYC dated on 2014-11-04: AstraZeneca, Pharmacyclics And Janssen Partner On Immuno-Oncology Combination Trials With IMBRUVICA

Financial news for PCYC dated on 2014-10-27: Wainwright Sees TG Therapeutics As Take-Out Target

Financial news for PCYC dated on 2014-10-20: Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA

Financial news for PCYC dated on 2014-10-17: Pharmacyclics Inc. Announces The EU Has Granted Marketing Approval For IMBRUVICA

Financial news for PCYC dated on 2014-10-16: Pharmacyclics Enters Into Agreement With Roche To Evaluate IMBRUVICA And GAZYVA In Lymphoma And Leukemia

Financial news for PCYC dated on 2014-10-13: Bristol-Myers, Pharmacyclics, Janssen Report Clinical Collaboration of Evaluate OPDIVO, IMBRUVICA in NHL

Financial news for PCYC dated on 2014-09-25: Pharmacyclics and Servier Agree To Conclude Pan-HDAC Inhibitor Collaboration

Financial news for PCYC dated on 2014-09-12: Deutsche Bank Issues Mid-Day Note, Says Pharmacyclics' Imbruvica Scripts Suggest Q3 Sales in \$136-178M Range

Financial news for PCYC dated on 2014-09-11: UPDATE: Morgan Stanley Reiterates On Pharmacyclics, Inc. Following VA Contract News

Financial news for PCYC dated on 2014-09-10: Bloomberg First Word Highlighting FDA Orphan Drug Designation for Pharmacyclic's Ibrutinib

Financial news for PCYC dated on 2014-09-10: US Government \$3.8B Contract Awarded to Pharmacyclics as Per FedBizOps Website

Financial news for PCYC dated on 2014-09-04: SunTrust Robinson Humphrey Initiates Coverage on Pharmacyclics, Inc. at Buy

Financial news for PCYC dated on 2014-08-20: Target Expected To Be Right On Target With Earnings

Financial news for PCYC dated on 2014-08-18: Pharmacyclics Appoints Chief Commercial Officer

Financial news for PCYC dated on 2014-08-01: Wallachbeth Capital Upgrades Pharmacyclics, Inc. to Buy, Maintains \$160.00 PT

Financial news for PCYC dated on 2014-07-31: Pharmacyclics, Inc. Reports Q2 EPS of \$(0.26) vs \$(0.22) Est; Revenue of \$113.0M vs \$97.32M Est

Financial news for PCYC dated on 2014-07-31: PCYC Reports \$0.26 Loss vs Street Est. Loss .19

Financial news for PCYC dated on 2014-07-28: Pharmacyclics Reports FDA Has Granted Full Approval for IMBRUVICA for Two Indications

Financial news for PCYC dated on 2014-07-28: FDA Expands Approved Use, Labeling of Imbruvica For Chronic Lymphocytic Leukemia

Financial news for PCYC dated on 2014-07-25: Pharmacyclics Reports EMA Positive Opinion for IMBRUVIA

Financial news for PCYC dated on 2014-07-25: EU Medicines Agency Recommends Johnson & Johnson, Pharmacyclics Leukaemia Drug Ibrutinib

Financial news for PCYC dated on 2014-06-30: Credit Suisse Raises Q2 Imbruvica Sales Forecast For Pharmacyclics

Financial news for PCYC dated on 2014-06-09: Pharmacyclics Announces FDA Acceptance of IMBRUVICA's sNDA, Priority Review Granted

Financial news for PCYC dated on 2014-06-03: UPDATE: Morgan Stanley Reiterates On Pharmacyclics Following Investor Event

Financial news for PCYC dated on 2014-06-02: Morning Market Movers

Financial news for PCYC dated on 2014-06-02: UPDATE: Morgan Stanley Reiterates On Pharmacyclics On ASCO Data

Financial news for PCYC dated on 2014-06-02: UPDATE: Pharmacyclics Shares Rise 9% on Positive IMBRUVICA Data Presented at ASCO

Financial news for PCYC dated on 2014-05-31: Pharmacyclics, JNJ Announce IMBRUVICA Shows Durable, Long-Term Responses for Patients with CLL

Financial news for PCYC dated on 2014-05-29: 3 More Surges In Biotech Short Interest (AMGN, MDVN, PCYC)

Financial news for PCYC dated on 2014-05-27: UPDATE: Morgan Stanley Reiterates On Pharmacyclics Following IMS Launch Analysis

Financial news for PCYC dated on 2014-05-27: Benzinga's Top Downgrades

Financial news for PCYC dated on 2014-05-27: RBC Capital Downgrades Pharmacyclics to Sector Perform, Lowers PT to \$95.00

Financial news for PCYC dated on 2014-05-23: Mid-Afternoon Market Update: Nimble Storage Rallies As Pharmacyclics Shows Weakness

Financial news for PCYC dated on 2014-05-20: Pharmacyclics Names Gregory Wade as Head of BizDev

Financial news for PCYC dated on 2014-05-11: Surges In Biotech Short Interest (INCY, PCYC, REGN)

Financial news for PCYC dated on 2014-05-05: Morgan Stanley Maintains Equal-weight on Pharmacyclics, Inc., Lowers PT to \$100.00

Financial news for PCYC dated on 2014-05-02: Piper Jaffray Downgrades Pharmacyclics, Inc. to Neutral

Financial news for PCYC dated on 2014-05-02: PREVIEW: Pharmacyclics to Resume Trading at 8:30 AM ET

Financial news for PCYC dated on 2014-05-02: Pharmacyclics Reports Received Milestone Payments of \$445M, May Get Added Payments of \$380M

Financial news for PCYC dated on 2014-05-02: Pharmacyclics, Inc. Reports Q1 EPS of \$0.23 vs \$0.17 Est; Revenue of \$119.40M vs \$105.38M Est

Financial news for PCYC dated on 2014-05-02: Pharmcyclics Shares Halted News Pending

Financial news for PCYC dated on 2014-04-10: Mid-Afternoon Market Update: Markets Continue to Take a Beating as Rite Aid Moves Higher

Financial news for PCYC dated on 2014-04-10: Mid-Day Market Update: Rite Aid Shares Gain On Upbeat Earnings; Imperva Drops

Financial news for PCYC dated on 2014-04-08: Pharmacyclics Says sNDA for Imbruvica Submitted to US FDA

Financial news for PCYC dated on 2014-04-08: Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA with Phase III CLL Study Data

Financial news for PCYC dated on 2014-03-27: Morgan Stanley's Top Biotech Pick is Biogen

Financial news for PCYC dated on 2014-03-27: Morgan Stanley Initiates Coverage on Pharmacyclics, Inc. at Equal-weight, Announces \$120.00 PT

Financial news for PCYC dated on 2014-03-26: Morgan Stanley Starts Pharmacyclics With Equal-Weight; \$120 PT -Reuters

Financial news for PCYC dated on 2014-03-26: Celgene, Pharmacyclics Lead Biotech Short Interest Trend (CELG, MDVN, PCYC)

Financial news for PCYC dated on 2014-03-19: Kiplinger's Tom Petruno Breaks Down The Best Bull Market Stocks

Financial news for PCYC dated on 2014-02-20: Pharmacyclics, Inc. Reports Q1 EPS of \$0.95 vs \$0.67 Est; Revenue of \$123.60M vs \$85.69M Est

Financial news for PCYC dated on 2014-02-18: FDA Approvals And Changes For The Week Ending February 14, 2014

Financial news for PCYC dated on 2014-02-14: Pharmacyclics to Report Q4, Year End 2013 Results on Thursday, February 20, 2014, After the Market Close

Financial news for PCYC dated on 2014-02-13: BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

Financial news for PCYC dated on 2014-02-12: UPDATE: Pharmacyclics Announces Will Receive \$60M Milestone Payment Related to J&J's Imbruvica Deal

Financial news for PCYC dated on 2014-02-12: UPDATE: FDA Approves Pharmacyclics' IMBRUVICA as Single Agent for Patients with Chronic Lymphocytic Leukemia

Financial news for PCYC dated on 2014-02-12: UPDATE: FDA Approves Imbruvica to Treat Chronic Lymphocytic Leukemia

Financial news for PCYC dated on 2014-02-12: Shares of Pharmacyclics On the Move Higher Following FDA Okay for Imbruvica

Financial news for PCYC dated on 2014-02-12: Pharmacyclics Spikes Higher

Financial news for PCYC dated on 2014-02-12: FDA Issues Okay for JanssenMD's Imbruvica for Chronic Lymphocytic Leukemia

Financial news for PCYC dated on 2014-01-08: Nomura Initiates Coverage on Pharmacyclics, Inc. at Buy, Announces \$137.00 PT

Financial news for PCYC dated on 2014-01-08: ETF Outlook for Wednesday, January 8, 2014 (ROBO, PBE, SMH, EUFN)

Financial news for PCYC dated on 2014-01-07: Market Wrap For January 7: Markets Reverse 3-Day Slump

Financial news for PCYC dated on 2014-01-07: Shares of Pharmacyclics Have Resumed, Now Up 14%

Financial news for PCYC dated on 2014-01-07: Shares of Pharmacyclics Have Been Halted on Limit-Up Limit-Down Trading Pause

Financial news for PCYC dated on 2014-01-07: Shares of Pharmacyclics Resume Trade Up 5%

Financial news for PCYC dated on 2014-01-07: J&J Says IDMC Recommends Early Stopping of Pharmacyclics' Phase 3 Study

Financial news for PCYC dated on 2014-01-07: Pharmacyclics to Resume Trading at 10:00 AM ET

Financial news for PCYC dated on 2014-01-07: UPDATE: Pharmacyclics Says Primary Endpoint Met in Phase III Trial of IMBRUVICA

Financial news for PCYC dated on 2014-01-07: Pharmacyclics Announces Independent Data Monitoring Committee Has Recommended Phase III Study of IMBRUVICA Be Stopped Early Based on Statistically Significant Improvement in Progress Free, Overall Survival

Financial news for PCYC dated on 2014-01-07: Pharmacyclics Halted News Pending

Financial news for PCYC dated on 2013-12-26: Rising Short Interest In Pharmacyclics, Other Biotechs (AMGN, GILD, PCYC)

Financial news for PCYC dated on 2013-12-18: Wallachbeth Capital Initiates Coverage on Pharmacyclics, Inc. at Hold, Announces \$108.00 PT

Financial news for PCYC dated on 2013-12-11: Biogen Idec, Pharmacyclics See Surges In Short Interest (BIIB, CELG, PCYC)

Financial news for PCYC dated on 2013-12-09: Pharmacyclics Announces Ibrutinib Frontline Chronic Lymphocytic Leukemia Study Results Published in The Lancet Oncology

Financial news for PCYC dated on 2013-11-27: UPDATE: Piper Jaffray Initiates Coverage on Pharmacyclics as 2014 Biotech Sector Outlook Remains Strong

Financial news for PCYC dated on 2013-11-26: Piper Jaffray Reinstates Overweight on Pharmacyclics, Inc.

Financial news for PCYC dated on 2013-11-15: WuXi to Partner with Pharmacyclics

Financial news for PCYC dated on 2013-11-14: Wedbush Reiterates on Pharmacyclics as IMBRUVICA Approved for Mantle Cell Lymphoma

Financial news for PCYC dated on 2013-11-13: Market Wrap For November 13: Markets Await Janet Yellen's Big Day Thursday

Financial news for PCYC dated on 2013-11-13: The U.S. Food and Drug Administration Approves Pharmacyclics Product For Treatment of Disease

Financial news for PCYC dated on 2013-11-13: Pharmacyclics Spiking Following Resumption; Shares Currently Up Over 3.3%

Financial news for PCYC dated on 2013-11-13: Pharmacyclics Resumes Trading

Financial news for PCYC dated on 2013-11-13: PREVIEW: Pharmacyclics to Resume Trading at 1:10 PM ET

Financial news for PCYC dated on 2013-11-13: UPDATE: Pharmacyclics Will Hold 1PM Call to Discuss FDA Approval of IMBRUVICA

Financial news for PCYC dated on 2013-11-13: Pharmacyclics, J&J's Janssen Now Confirming FDA Approval of IMBRUVICA

Financial news for PCYC dated on 2013-11-13: Pharmacyclics Halted News Pending

Financial news for PCYC dated on 2013-11-13: FDA Approves Ibrutinib for MCL

Financial news for PCYC dated on 2013-11-12: Gilead Sciences Leads In Rising Short Interest Among Biotechs

Financial news for PCYC dated on 2013-11-08: Shares of Pharmacyclics Jump 5% to Over \$120 Following Better-Than-Expected Q3 Results

Financial news for PCYC dated on 2013-10-25: Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, PCYC)

Financial news for PCYC dated on 2013-10-11: Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

Financial news for PCYC dated on 2013-10-11: Option Alert: Pharmacyclics October 125 Put; 2,000 Contracts Traded @\$2.50; Currently \$129.80

Financial news for PCYC dated on 2013-10-11: Goldman Sachs Upgrades Pharmacyclics, Inc. to Buy, Raises PT to \$170.00

Financial news for PCYC dated on 2013-10-04: Wells Fargo Initiates Coverage on

Pharmacyclics, Inc. at Outperform

Financial news for PCYC dated on 2013-09-26: UPDATE: J.P. Morgan Initiates Coverage on Pharmacyclics on Ibrutinib Potential

Financial news for PCYC dated on 2013-09-26: Stocks Hitting 52-Week Highs

Financial news for PCYC dated on 2013-09-26: Benzinga's Top Initiations

Financial news for PCYC dated on 2013-09-26: Deutsche Bank Initiates Coverage on Pharmacyclics, Inc. at Buy, Announces \$170.00 PT

Financial news for PCYC dated on 2013-09-26: JP Morgan Initiates Coverage on Pharmacyclics, Inc. at Overweight, Announces \$142.00 PT

Financial news for PCYC dated on 2013-09-25: BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)

Financial news for PCYC dated on 2013-09-24: UPDATE: William Blair Initiates Coverage on Pharmacyclics on Good Market Position for Ibrutinib

Financial news for PCYC dated on 2013-09-24: William Blair Initiates Coverage on Pharmacyclics, Inc. at Outperform, Announces \$143.00 PT

Financial news for PCYC dated on 2013-09-24: William Blair Initiates Coverage on Pharmacyclics, Inc. at Outperform, ANn \$143.00 PT

Financial news for PCYC dated on 2013-09-23: William Blair Initiates Coverage on Pharmacyclics, Inc. at Outperform

Financial news for PCYC dated on 2013-09-14: Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, CELG, PCYC)

Financial news for PCYC dated on 2013-09-04: Pharmacyclics Shares Push Over \$118 as Lazard Upgrades to Buy, Sets \$141 Target

Financial news for PCYC dated on 2013-08-29: FDA Accepts Pharmacyclics NDA Filing for Ibrutinib in Two B-cell Malignancies

Financial news for PCYC dated on 2013-08-27: Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, VRTX)

Financial news for PCYC dated on 2013-08-12: Royalty Pharma Partners with Aisling Capital and Clarus Ventures in Recent Ibrutinib Royalty Purchase

Financial news for PCYC dated on 2013-07-31: Pharmacyclics, Inc. Reports Q2 EPS of \$0.26 Which May Not Compare \$(0.07) Est; Revenue of \$54.70M Which May Not Compare \$52.0M Est

Financial news for PCYC dated on 2013-07-26: Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)

Financial news for PCYC dated on 2013-07-17: Kris Jenner of Rock Springs Capital Mentioning Vertex, Gilead, Pharmacyclics

Financial news for PCYC dated on 2013-07-11: Short Interest Rises in Gilead Sciences, Onyx Pharmaceuticals (BIIB, GILD, ONXX)

Financial news for PCYC dated on 2013-07-10: Market Wrap for Wednesday, July 10: Stocks Whipsaw Around FOMC Minutes, But Finished Nearly Unchanged

Financial news for PCYC dated on 2013-07-10: A Peek Into The Market Before The Trading Starts

Financial news for PCYC dated on 2013-07-10: Pharmacyclics Names Jesse McGreivy Chief Medical Officer

Financial news for PCYC dated on 2013-07-10: Pharmacyclics Submits NDA for Ibrutinib

Financial news for PCYC dated on 2013-07-01: RBC Sees Positives for Pharmacyclics Amid News of Rejected Offer for Onyx from Amgen

Financial news for PCYC dated on 2013-06-26: Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, VRTX)

Financial news for PCYC dated on 2013-06-20: UPDATE: Pharmacyclics Shows Ibrutinib Phase II Best Response Rate 83%, Data Shows Highly Active, Well-Tolerated

Financial news for PCYC dated on 2013-06-20: Pharmacyclics Shows Ibrutinib Phase II

Best Response Rate 83%, Data Shows Highly Active, Well-Tolerated

Financial news for PCYC dated on 2013-06-20: Pharmacyclics' Phase 2 Mantle Cell Lymphoma Study Results Published in New England Journal of Medicine

Financial news for PCYC dated on 2013-06-19: Research Abstracts, Phase 2 Results, and Market Availability of Formulations and Treatments- Research Report on Teva, Forest, Pharmacyclics, Cubist, and Dr. Reddy's

Financial news for PCYC dated on 2013-06-12: Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)

Financial news for PCYC dated on 2013-05-31: Pharmacyclics Wins FDA Orphan Status for Product for Type of Lymphoma

Financial news for PCYC dated on 2013-05-29: Short Interest in Vertex Rises, in Biogen Idec Falls

Financial news for PCYC dated on 2013-05-20: Pharmacyclics Shares Move Higher on FDA Orphan Designation for Ibrutinib for Treatment of Multiple Myeloma

Financial news for PCYC dated on 2013-05-13: Benzinga's Top Upgrades

Financial news for PCYC dated on 2013-05-13: RBC Capital Upgrades Pharmacyclics, Inc. to Outperform, Raises PT to \$100.00

Financial news for PCYC dated on 2013-05-11: Short Interest in Vertex Rises, in Celgene Falls

Financial news for PCYC dated on 2013-05-07: Goldman Sachs Initiates Coverage on Pharmacyclics, Inc. at Neutral, Announces \$80.00 PT

Financial news for PCYC dated on 2013-05-06: Three Top Performing Healthcare Stocks to Watch

Financial news for PCYC dated on 2013-05-01: Pharmacyclics, Inc. Sees Q2 EPS \$0.00 vs \$0.02 Est

Financial news for PCYC dated on 2013-05-01: Pharmacyclics, Inc. Reports Q1 EPS of \$(0.40) Which May Not Compare \$(0.17) Est

Financial news for PCYC dated on 2013-04-26: Short Sellers Move into Celgene, Regeneron

Financial news for PCYC dated on 2013-04-23: Stocks to Watch for April 23, 2013

Financial news for PCYC dated on 2013-04-22: 9 Technical Setups for the Week Ahead

Financial news for PCYC dated on 2013-04-11: A Peek Into The Market Before The Trading Starts

Financial news for PCYC dated on 2013-04-11: Pharmacyclics Triggers \$50M Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study

Financial news for PCYC dated on 2013-04-10: Short Sellers Move Out of Amgen, Celgene, Pharmacyclics

Financial news for PCYC dated on 2013-04-08: Pharmacyclics Offers Result from Phase II Trial of Ibrutinib

Financial news for PCYC dated on 2013-04-08: Pharmacyclics Receives Third Breakthrough Therapy Designation for Ibrutinib from FDA

Financial news for PCYC dated on 2013-03-28: Short Sellers Dump Amgen, Focus on Celgene, Gilead Sciences

Financial news for PCYC dated on 2013-03-23: Moves in Smaller Health Care Stocks (ANAC, HALO, PBXI, QCOR)

Financial news for PCYC dated on 2013-03-20: UPDATE: Wedbush Raises PT on Pharmacyclics on Ibrutinib Bullishness

Financial news for PCYC dated on 2013-03-20: Morgan Stanley Initiated Coverage on Pharmacyclics with an Equalweight Rating

Financial news for PCYC dated on 2013-03-19: Morgan Stanley Initiates Coverage on Pharmacyclics, Inc. at Equal-weight

Financial news for PCYC dated on 2013-03-12: Short Interest Swings in Biotech Stocks

(AMGN, CELG, PCYC)

Financial news for PCYC dated on 2013-03-08: Pharmacyclics Prices 2.2M Shares at \$94.20/Share

Financial news for PCYC dated on 2013-03-07: Pharmacyclics Begins 2.2M Share Offering

Financial news for PCYC dated on 2013-02-28: Short Interest Swings in Biotech Stocks (ALXN, AMGN, CELG)

Financial news for PCYC dated on 2013-02-21: Abbott to Collaborate with Janssen Pharma, Pharmacyclics to Develop Companion Test for Investigational Leukemia Therapy

Financial news for PCYC dated on 2013-02-19: From Earlier: Leerink Swann Downgrades Pharmacyclics, Inc. to Market Perform

Financial news for PCYC dated on 2013-02-14: Earnings Scheduled For February 14, 2013

Financial news for PCYC dated on 2013-02-13: Some Possible Break Out Candidates

Financial news for PCYC dated on 2013-02-12: Pharmacyclics Granted Breakthrough Therapy Designation from FDA for Ibrutinib Monotherapy

Financial news for PCYC dated on 2013-02-12: Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

Financial news for PCYC dated on 2013-02-08: From Earlier: JMP Securities Initiates Coverage on Pharmacyclics, Inc. at Market Outperform, Announces \$104.00 PT

Financial news for PCYC dated on 2013-01-26: Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

Financial news for PCYC dated on 2013-01-15: UPDATE: Credit Suisse Initiates Pharmacyclics at Outperform on Pure Play Potential

Financial news for PCYC dated on 2013-01-15: Credit Suisse Initiates Coverage on Pharmacyclics, Inc. at Outperform, Announces \$79.00 PT

Financial news for PCYC dated on 2013-01-15: Credit Suisse Initiates Coverage on Pharmacyclics, Inc. at Outperform, Announces \$79.00 PT

Financial news for PCYC dated on 2013-01-14: Lazard Capital Markets Downgrades Pharmacyclics, Inc. to Neutral

Financial news for PCYC dated on 2012-12-28: Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

Financial news for PCYC dated on 2012-12-12: Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

Financial news for PCYC dated on 2012-12-11: Pharmacyclics Announces Updated Results for BTK Inhibitor Ibrutinib

Financial news for PCYC dated on 2012-12-11: Pharmacyclics(r) Announces Updated Results for BTK Inhibitor Ibrutinib at American Society of Hematology (ASH) Annual Meeting

Financial news for PCYC dated on 2012-12-08: Pharmacyclics Presents Positive Data at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials

Financial news for PCYC dated on 2012-12-07: UPDATE: Dawson James Initiates Pharmacyclics at Market Outperform on Ibrutinib Confidence

Financial news for PCYC dated on 2012-12-07: Dawson James Initiates Coverage on Pharmacyclics, Inc. at Market Outperform, Announces \$101.00 PT

Financial news for PCYC dated on 2012-11-12: Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)

Financial news for PCYC dated on 2012-11-05: Mid-Afternoon Market Update: Markets Rally, Vringo Jumps

Financial news for PCYC dated on 2012-11-05: Roth Capital Upgrades Pharmacyclics from Neutral to Buy, Raises PT from \$59 to \$63

Financial news for PCYC dated on 2012-11-05: Mid Morning Market Update: Markets Decline, Stifel Financial Acquires KBW

Financial news for PCYC dated on 2012-11-05: CORRECTION: Pharmacyclics Reports Q1 EPS

\$1.07 vs \$1.10 Est; Revenues \$102.7M vs \$99.7M Est

Financial news for PCYC dated on 2012-11-05: FROM EARLIER: Pharmacyclics Reports Q1 EPS \$1.02 May Not Compare to \$0.75 Est; Revenues \$102.7M vs \$87.64M Est

Financial news for PCYC dated on 2012-11-05: Earnings Scheduled For November 5, 2012

Financial news for PCYC dated on 2012-11-01: Benzinga's Top Initiations

Financial news for PCYC dated on 2012-11-01: UPDATE: Piper Jaffray Initiates Pharmacyclics at Buy

Financial news for PCYC dated on 2012-10-31: Piper Jaffray Initiates Coverage on Pharmacyclics at Overweight, Announces PT of \$83

Financial news for PCYC dated on 2012-10-25: Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)

Financial news for PCYC dated on 2012-10-15: Pharmacyclics Triggers \$50M Payment from Johnson & Johnson

Financial news for PCYC dated on 2012-10-15: Pharmacyclics Triggers \$50M Payment from Johnson & Johnson

Financial news for PCYC dated on 2012-10-15: Short Interest Swings in Biotech Stocks (BIIB, CELG, GILD)

Financial news for PCYC dated on 2012-09-26: Short Interest in Biotech Firms Resumes (BIIB, GILD, ILMN, REGN)

Financial news for PCYC dated on 2012-09-14: Pharmacyclics Spikes Lower

Financial news for PCYC dated on 2012-09-07: UPDATE: Wedbush Securities Reiterates Outperform Rating, Raises PT on Pharmacyclics

Financial news for PCYC dated on 2012-09-07: Wedbush Securities Maintains Pharmacyclics at Outperform, Raises PT from \$55 to \$93

Financial news for PCYC dated on 2012-09-06: Pharmacyclics Spikes Lower

Financial news for PCYC dated on 2012-09-05: Pharmacyclics Reports Q4 EPS \$-0.24 vs \$-0.27 Est; Revenues \$2.12M vs \$3.49M Est

Financial news for PCYC dated on 2012-08-27: Short Interest in Biotech Firms on the Rise

Financial news for PCYC dated on 2012-08-24: UPDATE: Stifel Nicolaus Initiates Pharmacyclics at Hold; Valuation Full

Financial news for PCYC dated on 2012-08-24: Stifel Nicolaus Initiates Coverage on Pharmacyclics at Hold

Financial news for PCYC dated on 2012-08-23: Pharmacyclics Spikes to 52-Week High

Financial news for PCYC dated on 2012-08-20: UPDATE: Rodman & Renshaw Raises PT to \$75 on Pharmacyclics on SPARK Phase III Trial

Financial news for PCYC dated on 2012-08-20: Rodman & Renshaw Maintains Pharmacyclics at Outperform, Raises PT to \$75

Financial news for PCYC dated on 2012-08-20: Pharmacyclics Triggers Significant Milestone Payment For Mantle Cell Lymphoma Clinical Trial

Financial news for PCYC dated on 2012-08-14: Rodman & Renshaw Maintains Pharmacyclics at Market Outperform, Raises PT to \$59

Financial news for PCYC dated on 2012-08-14: Pharmacyclics Appoints Joshua T. Brumm Executive Vice President of Finance

Financial news for PCYC dated on 2012-08-01: Financial Breakfast: Morning News Summary for August 1, 2012

Financial news for PCYC dated on 2012-08-01: Pharmacyclics(r) Triggers Significant Milestone Payment and Provides Clinical Program Update

Financial news for PCYC dated on 2012-07-11: Option Alert: Pharmacyclics November 25 Put; Block Trade: 5,600 Contracts @0.35; Currently \$54.55

Financial news for PCYC dated on 2012-07-10: Dendreon, Pharmacyclics and Other

Biotech Takeover Targets

Financial news for PCYC dated on 2012-07-03: 6 Chart Set-ups to Watch on Thursday

Financial news for PCYC dated on 2012-07-02: Five stocks to keep an eye on

Financial news for PCYC dated on 2012-06-29: Stock setups to watch next week

Financial news for PCYC dated on 2012-06-29: Pharmacyclics Hits New 52-Week High, Crossing \$55.00

Financial news for PCYC dated on 2012-06-28: Pharmacyclics Spikes Lower

Financial news for PCYC dated on 2012-06-27: 4 Breakout Stocks To Watch Thursday

Financial news for PCYC dated on 2012-06-25: Trade Setups for Tuesday 26th June 2012

Financial news for PCYC dated on 2012-06-21: Trade setups to keep on your trading watch list

Financial news for PCYC dated on 2012-06-12: Option Alert: Pharmacyclics January 2013 15/18 Put Spread; Block Trade: 5,000/3,500 Contracts; Currently \$39.50

Financial news for PCYC dated on 2012-06-08: Five Swing Trade Setups to Watch Next Week

Financial news for PCYC dated on 2012-06-07: Pharmacyclics Trading 7.4% Higher on Heavy Volume; Currently at \$37.35

Financial news for PCYC dated on 2012-06-07: Brean Murray Carret Initiates Pharmacyclics at Buy, \$80 PT

Financial news for PCYC dated on 2012-06-06: UPDATE: Wedbush Reiterates Outperform, Raises PT to \$55 on Pharmacyclics on Ibrutinib Catalyst

Financial news for PCYC dated on 2012-06-06: Wedbush Securities Maintains Pharmacyclics at Outperform, Raises PT from \$40 to \$55

Financial news for PCYC dated on 2012-06-05: Rodman & Renshaw Raises PT on Pharmacyclics to \$40 to \$38, Maintains Market Outperform

Financial news for PCYC dated on 2012-06-04: Pharmacyclics(r) Announces Updated Results for BTK Inhibitor Ibrutinib (PCI-32765) at ASCO

Financial news for PCYC dated on 2012-06-01: 6 Trade Setups To Watch next week

Financial news for PCYC dated on 2012-05-23: Thursday's Stocks To Watch, May 24 2012

Financial news for PCYC dated on 2012-05-22: Wednesday's Stocks To Watch, May 23 2012

Financial news for PCYC dated on 2012-05-21: Tuesday's Stocks To Watch, May 22 2012

Financial news for PCYC dated on 2012-05-17: Social Media Outlook for Thursday 17 (PCYC, DRI, MLM, SPLS)

Financial news for PCYC dated on 2012-05-17: Rodman & Renshaw Maintains Pharmacyclics at Market Outperform, Raises PT from \$38 to \$40

Financial news for PCYC dated on 2012-05-15: Top 10 Small Cap ETFs

Financial news for PCYC dated on 2012-05-15: Churchill Downs, Luxottica and Others Analysts Are Bullish On

Financial news for PCYC dated on 2012-05-14: Honda, Movado and Others Analysts Are Bullish On

Financial news for PCYC dated on 2012-04-11: Pharmacyclics Gets FDA Orphan Drug Status for CLL Treatment

Financial news for PCYC dated on 2012-03-20: UPDATE: Wedbush Raises Pharmacyclics PT

Financial news for PCYC dated on 2012-03-20: Wedbush Securities Maintains Pharmacyclics at Outperform, Raises PT from \$25 to \$40

Financial news for PCYC dated on 2012-03-20: Hearing Wedbush Making Positive Comments about Pharmacyclics

Financial news for PCYC dated on 2012-03-19: Notable Put Options Activity in Pharmacyclics

Financial news for PCYC dated on 2012-03-05: Weekly Traders Homework: Small-Caps Correcting (w/ Economic Calendar and Stock Radar)

Financial news for PCYC dated on 2012-02-15: Option Alert: Pharmacyclics May 16 Put Block Trade; 7,500 Contracts

Financial news for PCYC dated on 2012-02-11: Five Interesting charts to watch next week

Financial news for PCYC dated on 2012-02-10: BlackRock Discloses 5.19% Stake in Pharmacyclics -Filing

Financial news for PCYC dated on 2012-02-06: Rodman & Renshaw Maintains Outperform, \$22 PT on Pharmacyclics

Financial news for PCYC dated on 2012-01-26: Rodman & Renshaw Comments on Pharmacyclics, Maintains PT

Financial news for PCYC dated on 2012-01-12: Option Alert: Pharmacyclics August 14 Put Block Trade; 5,000 Contracts

Financial news for PCYC dated on 2012-01-11: Pharmacyclics Hits 52-Week High of \$16.25

Financial news for PCYC dated on 2011-12-19: Rodman & Renshaw Maintains Market Outperform on Pharmacyclics

Financial news for PCYC dated on 2011-12-19: Pharmacyclics Inc. Receives Issue Notice of Significant Bruton's Tyrosine Kinase Patent

Financial news for PCYC dated on 2011-12-15: Rodman & Renshaw Raises PT on Pharmacyclics to \$22

Financial news for PCYC dated on 2011-12-14: Rodman & Renshaw Maintains Outperform, \$20 PT on Parmacyclics

Financial news for PCYC dated on 2011-12-13: Wedbush Increases Pharmacyclics PT, Reiterates Outperform, Adds To "Best Ideas"

Financial news for PCYC dated on 2011-12-13: Edison Investment Research Comments on Pharmacyclics

Financial news for PCYC dated on 2011-12-13: Pharmacyclics Announces Updated Results for BTK Inhibitor PCI-32765 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

Financial news for PCYC dated on 2011-12-12: Pharmacyclics Reports Interim Phase II Trial Results for BTK Inhibitor PCI-32765 in Mantle Cell Lymphoma at American Society of Hematology Annual Meeting

Financial news for PCYC dated on 2011-12-09: End-of-Day Market Summary for December 9, 2011

Financial news for PCYC dated on 2011-12-09: Afternoon Movers; Positive Euro News

Financial news for PCYC dated on 2011-12-09: Global Hunter Downgrades Pharmacyclics to Neutral

Financial news for PCYC dated on 2011-12-09: RBC Capital Downgrades Pharmacyclics to Sector Perform

Financial news for PCYC dated on 2011-12-08: Janssen Says Deal to Cut Johnson & Johnson 2011 EPS by \$0.04-\$0.05

Financial news for PCYC dated on 2011-12-08: Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech

Financial news for PCYC dated on 2011-12-07: Rodman & Renshaw Initiates Pharmacyclics at Market Outperform, \$20 PT

Financial news for PCYC dated on 2011-11-11: Notable Put Options Activity in Pharmacyclics

Financial news for PCYC dated on 2011-09-21: Wait-and-See Action 09-21-2011

Financial news for PCYC dated on 2011-09-12: Pharmacyclics Reports Q4 EPS \$(0.15) vs \$(0.13) Est, Revenue \$1.39M

Financial news for PCYC dated on 2011-07-28: Few Trade Ideas for Friday, July 29

Financial news for PCYC dated on 2011-07-21: Stock Watch List For Friday, July 22

Financial news for PCYC dated on 2011-07-15: Pharmacyclics Files \$150M Mixed Securities Shelf

Financial news for PCYC dated on 2011-07-12: Stocks to Watch for Wednesday 07/13/11: Fresh 52 Week Highs and Lows

Financial news for PCYC dated on 2011-07-11: Options Brief: Pharmacyclics

Financial news for PCYC dated on 2011-07-10: Stocks to Watch for Monday 07/11/11: Fresh 52 Week Highs and Lows

Financial news for PCYC dated on 2011-07-01: Friday's Put/Call Ratio Leaders

Financial news for PCYC dated on 2011-06-30: Thursday's Put/Call Ratio Leaders

Financial news for PCYC dated on 2011-06-28: Stocks to Watch for 6/28/11: Fresh 52 Week Highs and Lows

Financial news for PCYC dated on 2011-06-27: NASDAQ Stocks Hitting 52-Week Highs

Financial news for PCYC dated on 2011-06-26: 30 Stocks for This Week: Investment and Trading Opportunities

Financial news for PCYC dated on 2011-06-23: Hearing Neeham Positive on Pharmacyclics and Management w/ \$12 PT

Financial news for PCYC dated on 2011-06-20: Stocks to Watch for 6/20/11: Fresh 52-Week Highs and Lows

Financial news for PCYC dated on 2011-06-17: Pharmacyclics Announces Results of Registered Direct Offering of 6.5M Shares

Financial news for PCYC dated on 2011-06-16: Stocks to Watch for 6/16/11: Fresh 52-Week Highs and Lows

Financial news for PCYC dated on 2011-06-15: Stocks Hitting 52-Week Highs

Financial news for PCYC dated on 2011-06-14: Tuesday's Put/Call Ratio Leaders

Financial news for PCYC dated on 2011-06-07: Top Percentage Gainers and Losers as of 2pm 06/07/11

Financial news for PCYC dated on 2011-06-07: Top Percentage Gainers and Losers as of 12pm 06/07/11

Financial news for PCYC dated on 2011-06-06: Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765

Financial news for PCYC dated on 2011-05-27: Global Hunter Initiates Pharmacyclics At Buy, \$13 PT

Financial news for PCYC dated on 2011-05-19: Options Brief: Pharmacyclics Inc. (PCYC)

Financial news for PCYC dated on 2011-03-02: Pharmacyclics Announces Suspension of Further Advancement of PCI-45292

Financial news for PCYC dated on 2011-02-04: Pharmacyclics Reports Financial Results for Fiscal Second Quarter 2011

Financial news for PCYC dated on 2011-01-24: Monday's Put/Call Ratio Leaders (GDOT, DISCK, PFCB, CMED, PCYC)

Financial news for PCYC dated on 2011-01-10: Calls Purchased on Pharmacyclics Inc. (PCYC)

Financial news for PCYC dated on 2010-12-15: Options Brief: Pharmacyclics Inc. (PCYC)

Financial news for PCYC dated on 2010-12-07: Options Brief: Pharmacyclics Inc. (PCYC)

Financial news for PCYC dated on 2010-11-08: Pharmacyclics Reports Recent Developments and Financial Results for Fiscal First Quarter 2011: Loss of \$0.09 Per Share

Financial news for PCYC dated on 2010-10-26: Puts Purchased on Pharmacyclics Inc. (PCYC)

Financial news for PCYC dated on 2010-10-26: Tuesday's Put/Call Ratio Leaders (LINTA, GGB, PVH, MTL, PCYC)

Financial news for PCYC dated on 2010-10-19: Bearish MACD for Pharmacyclics - Tale of the Tape

Financial news for PCYC dated on 2010-09-13: Pharmacyclics Reports Financial Results for Fiscal 2010

Financial news for PCYC dated on 2010-09-13: Earnings Scheduled For September 13 (FUL, TRR, MTRX, PCYC, NTSC, MSB, LCI, LRN, GCOM, FEIM, FARM, CHP)

Financial news for PCYC dated on 2010-09-07: The Essential Biotech Sector Fall Preview

Financial news for PCYC dated on 2010-08-13: Puts Purchased on Pharmacyclics Inc. (PCYC)

Financial news for PCYC dated on 2010-08-09: Puts Sold on Pharmacyclics Inc. (PCYC)

Financial news for PCYC dated on 2010-07-06: Protection Purchased on Pharmacyclics Inc. (PCYC)

Financial news for PCYC dated on 2010-06-24: Calls Sold on Pharmacyclics Inc (PCYC)

Financial news for PCYC dated on 2010-06-16: As the Euro Goes -- So Goes... 06-16-2010

Financial news for PCYC dated on 2010-06-07: Mixed Call Activity on Pharmacyclics (PCYC)

Financial news for PCYC dated on 2010-02-12: Benzinga's Top Downgrades (MITI, VCLK, NILE, PCYC, CSTR)

Financial news for PCYC dated on 2010-02-05: Stocks That Created New 52-Week Highs (AIPC, KELYA, CTEL, SCBT)

Financial news for PCYC dated on 2010-01-13: Merck leads drug stocks up